The research program focuses on clinical trials involving new investigational agents for the treatment of a wide range of cancers. Active clinical trials include studies involving doxorubicin and taxol and agents that reverse resistance to these drugs, such as PSC 833.

Other interests include phase I and II studies using anti-sense DNA, targeting PKC-alpha in ovarian cancer and the role of gene-modified autologous T cells engineered to recognize the TAG-72 antigen on colon cancer cells.

• Cabebe E, Fisher GA "Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer." Expert Opin Investig Drugs 2007; 16: 4: 467-76 More
• Cupp JS, Koong AC, Fisher GA, Norton JA, Goodman KA "Tissue Effects after Stereotactic Body Radiotherapy using Cyberknife for Patients with Abdominal Malignancies." Clin Oncol (R Coll Radiol) 2007; More
• Cho CD, Fisher GA, Halsey J, Sikic BI "Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies." Invest New Drugs 2006; 24: 2: 117-23 More
• Street HH, Goris ML, Fisher GA, Wessels BW, Cho C, Hernandez C, Zhu HJ, Zhang Y, Nangiana JS, Shan JS, Roberts K, Knox SJ "Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer." Cancer Biother Radiopharm 2006; 21: 3: 243-56 More
• Wakelee H, Fisher GA "A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer." Invest New Drugs 2005; 23: 3: 241-2 More